State of Michigan Retirement System Reduces Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

State of Michigan Retirement System reduced its holdings in shares of DexCom, Inc. (NASDAQ:DXCMFree Report) by 0.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 105,600 shares of the medical device company’s stock after selling 200 shares during the quarter. State of Michigan Retirement System’s holdings in DexCom were worth $14,647,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. O Shaughnessy Asset Management LLC lifted its holdings in DexCom by 17.9% in the 3rd quarter. O Shaughnessy Asset Management LLC now owns 15,622 shares of the medical device company’s stock valued at $1,458,000 after purchasing an additional 2,371 shares in the last quarter. Advisors Asset Management Inc. lifted its stake in shares of DexCom by 10.8% during the 3rd quarter. Advisors Asset Management Inc. now owns 16,291 shares of the medical device company’s stock worth $1,520,000 after purchasing an additional 1,588 shares during the period. Alps Advisors Inc. lifted its stake in shares of DexCom by 6.3% during the 3rd quarter. Alps Advisors Inc. now owns 12,877 shares of the medical device company’s stock worth $1,201,000 after purchasing an additional 763 shares during the period. EULAV Asset Management boosted its holdings in shares of DexCom by 28.1% during the third quarter. EULAV Asset Management now owns 100,000 shares of the medical device company’s stock worth $9,330,000 after purchasing an additional 21,938 shares during the last quarter. Finally, Lido Advisors LLC grew its position in shares of DexCom by 1,485.9% in the third quarter. Lido Advisors LLC now owns 56,298 shares of the medical device company’s stock valued at $5,253,000 after purchasing an additional 52,748 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on DXCM. Citigroup upped their price objective on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Royal Bank of Canada started coverage on DexCom in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 target price on the stock. Raymond James lifted their price objective on DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research note on Friday, April 26th. UBS Group boosted their target price on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Finally, StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research note on Monday, June 10th. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $140.33.

Get Our Latest Stock Report on DexCom

DexCom Price Performance

Shares of DXCM opened at $112.49 on Wednesday. DexCom, Inc. has a 12 month low of $74.75 and a 12 month high of $142.00. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53. The stock has a fifty day moving average price of $122.32 and a 200 day moving average price of $125.58. The company has a market cap of $44.74 billion, a P/E ratio of 72.57, a PEG ratio of 2.77 and a beta of 1.16.

DexCom (NASDAQ:DXCMGet Free Report) last posted its earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The firm had revenue of $921.00 million during the quarter, compared to analyst estimates of $911.20 million. On average, research analysts forecast that DexCom, Inc. will post 1.78 earnings per share for the current year.

Insider Activity

In other news, EVP Matthew Vincent Dolan sold 1,990 shares of the company’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $137.81, for a total value of $274,241.90. Following the completion of the sale, the executive vice president now owns 42,377 shares in the company, valued at $5,839,974.37. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other DexCom news, EVP Matthew Vincent Dolan sold 1,990 shares of the company’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $137.81, for a total value of $274,241.90. Following the transaction, the executive vice president now owns 42,377 shares of the company’s stock, valued at $5,839,974.37. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Bridgette P. Heller sold 1,000 shares of the firm’s stock in a transaction on Friday, June 14th. The stock was sold at an average price of $113.55, for a total value of $113,550.00. Following the sale, the director now directly owns 25,349 shares of the company’s stock, valued at $2,878,378.95. The disclosure for this sale can be found here. Insiders sold 55,735 shares of company stock worth $7,619,347 over the last three months. Corporate insiders own 0.30% of the company’s stock.

DexCom Company Profile

(Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Featured Stories

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCMFree Report).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.